MedTrace Logo

The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia

NCT01065545 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-04-10

No results posted yet for this study

Summary

The purpose of this study is to determine the side effects of the study drug, clofarabine, when given by mouth to patients with acute myeloid leukemia (AML), in remission.

Conditions

Interventions

DRUG

Clofarabine

dose escalation, administered orally, once a day for 21 days per cycle (cycles begin every 28-49 days)

Sponsors & Collaborators

  • Loyola University

    collaborator OTHER

  • Rush University Medical Center

    collaborator OTHER

  • University of Illinois at Chicago

    collaborator OTHER

  • Genzyme, a Sanofi Company

    collaborator INDUSTRY

  • Northwestern University

    lead OTHER

Principal Investigators

  • Jessica Altman, MD · Northwestern University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01065545 on ClinicalTrials.gov